Aer Therapeutics discloses $3 million securities offering in SEC Form D filing

Aer Therapeutics, Inc., a Delaware corporation with its principal place of business at 8 Davis Dr in Research Triangle Park, North Carolina, filed a Form D notice with the Securities and Exchange Commission disclosing an exempt securities offering. The filing lists a date of first sale of 2026-08-07¹ and was signed on 2026-08-18.

The total offering amount and the total amount sold were both listed as $3,000,000, with $0 remaining to be sold.¹ The filing states that seven investors had already invested in the offering.¹ The company claimed the Rule 506(b) exemption under Regulation D.¹

The securities offered included debt as well as an option, warrant, or other right to acquire another security, and a security to be acquired upon exercise of such an option, warrant, or right.¹ The offering was not made in connection with a business combination transaction such as a merger or acquisition.¹

The filing reported $0 in sales commissions and finders' fees.¹ Use of proceeds was listed as $0 directed to executive officers, directors, or promoters, with the clarification that proceeds will be used for working capital, which may include normal compensation to executive officers.¹

The related persons named in the filing include Thomas Mathers as an executive officer and director, and John Fahy, Evan Caplan, Tim Shannon, and Christy Shaffer, each listed as a director.¹ The company identified its industry group as biotechnology within health care.¹

The Form D was signed by Thomas Mathers, identified as Chairman of the Board of Directors, on 2026-08-18.¹